Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation

Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation

Abstract Background The year-round respiratory syncytial virus (RSV) circulation in tropical regions leads to different transmission patterns and burden of disease among infants born very preterm. Methods We conducted a retrospective cohort study to estimate the effectiveness of palivizumab in preve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 2021-07, Vol.224 (2), p.279-287
Hauptverfasser: Yeo, Kee Thai, Yung, Chee Fu, Khoo, Poh Choo, Saffari, Seyed Ehsan, Sng, Jane Swee Peng, How, Mee See, Quek, Bin Huey
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal, Humanized - therapeutic use
Antiviral Agents - therapeutic use
Drug dosages
Gestation
Hospitalization
Humans
Infant
Infant, Newborn
Infant, Premature
Infants
Monoclonal antibodies
Neonates
Newborn babies
Palivizumab - therapeutic use
Premature babies
Prophylaxis
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - drug therapy
Respiratory Syncytial Virus Infections - prevention & control
Retrospective Studies
Tropical environment
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background The year-round respiratory syncytial virus (RSV) circulation in tropical regions leads to different transmission patterns and burden of disease among infants born very preterm. Methods We conducted a retrospective cohort study to estimate the effectiveness of palivizumab in preventing RSV hospitalization at 6 and 12 months after discharge, among infants born at
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa749